Safety of Nirmatrelvir-Ritonavir Administration in Children With Immunodeficiency and/or Comorbidities With SARS-CoV-2 Infection: A Retrospective Clinical Report
Our experience shows that N/R is reasonably safe in the pediatric population and could favor viral clearance, thus reducing the duration of infection.
Authors
- Tiziana Corsetti
- Paolo Palma (ORCID: https://orcid.org/0000-0002-3066-4719)
- Antonio Torelli
- Alberto Villani (ORCID: https://orcid.org/0000-0002-9120-0424)
- Emanuele Nicastri (ORCID: https://orcid.org/0000-0002-5606-8712)
- Leonardo Vallesi
- Marco Roversi (ORCID: https://orcid.org/0000-0003-0858-033X)
- Laura Lancella (ORCID: https://orcid.org/0000-0002-1662-4219)
- Paolo Rossi (ORCID: https://orcid.org/0000-0003-2620-7918)
- Stefania Bernardi (ORCID: https://orcid.org/0000-0001-5672-0881)
- Massimiliano Raponi (ORCID: https://orcid.org/0000-0002-7757-6978)
- Barbarella Lucarelli
- Federica Galaverna (ORCID: https://orcid.org/0000-0003-0717-2924)
- Carlo Federico Perno (ORCID: https://orcid.org/0000-0002-0825-5388)
- Antonio Musolino (ORCID: https://orcid.org/0000-0002-3316-957X)
Institutions
- University of Rome Tor Vergata (IT)
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- Bambino Gesù Children's Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- The Pediatric Infectious Disease Journal
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1097/inf.0000000000004657
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39